Literature DB >> 9100046

High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients.

P Bárány1, J C Divino Filho, J Bergström.   

Abstract

Inflammation is one of the major causes of resistance to erythropoietin (EPO) treatment. In the present study, the relationship between serum C-reactive protein (s-CRP) and the dose of recombinant human EPO required to maintain hemoglobin levels at approximately 12 g/dL was analyzed in 30 hemodialysis patients. The weekly EPO dose in patients with s-CRP > or = 20 mg/L was, on average, 80% higher than in patients with s-CRP less than 20 mg/L. The EPO doses and s-CRP were both inversely correlated to the levels of serum albumin and serum iron, suggesting that the principal mechanism by which inflammatory cytokines inhibit erythropoiesis is coupled to iron metabolism, ie, functional iron deficiency. Our results demonstrate the usefulness of s-CRP as a predictor of resistance to EPO treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9100046     DOI: 10.1016/s0272-6386(97)90339-5

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  42 in total

1.  Risk factors for high erythropoiesis stimulating agent resistance index in pre-dialysis chronic kidney disease patients, stages 4 and 5.

Authors:  Ana de Lurdes Agostinho Cabrita; Ana Pinho; Anabela Malho; Elsa Morgado; Marília Faísca; Hermínio Carrasqueira; Ana Paula Silva; Pedro Leão Neves
Journal:  Int Urol Nephrol       Date:  2010-07-17       Impact factor: 2.370

2.  Erythropoietin effectiveness index : a quantitative definition of resistance in haemodialysis patients with adequate iron stores.

Authors:  G R Bailie; C L Low; G Eisele
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

Review 3.  Statins, inflammation and kidney disease.

Authors:  Vera Krane; Christoph Wanner
Journal:  Nat Rev Nephrol       Date:  2011-05-31       Impact factor: 28.314

4.  Ergocalciferol decreases erythropoietin resistance in children with chronic kidney disease stage 5.

Authors:  Pornpimol Rianthavorn; Pantipa Boonyapapong
Journal:  Pediatr Nephrol       Date:  2013-02-19       Impact factor: 3.714

5.  Unexplained aspects of anemia of inflammation.

Authors:  Elizabeth A Price; Stanley L Schrier
Journal:  Adv Hematol       Date:  2010-03-24

6.  Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis.

Authors:  Elani Streja; Csaba P Kovesdy; Sander Greenland; Joel D Kopple; Charles J McAllister; Allen R Nissenson; Kamyar Kalantar-Zadeh
Journal:  Am J Kidney Dis       Date:  2008-08-29       Impact factor: 8.860

7.  Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients.

Authors:  Manoch Rattanasompattikul; Miklos Z Molnar; Joshua J Zaritsky; Parta Hatamizadeh; Jennie Jing; Keith C Norris; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Nephrol Dial Transplant       Date:  2012-10-08       Impact factor: 5.992

Review 8.  Past, present and future of erythropoietin use in the elderly.

Authors:  Angel L M de Francisco; Gema Fernandez Fresnedo; Emilio Rodrigo; Celestino Piñera; Milagros Heras; Rosa Palomar; Juan C Ruiz; Manuel Arias
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

9.  Homocysteine and C-reactive protein levels in haemodialysis patients.

Authors:  E Koulouridis; M Tzilianos; A Katsarou; I Costimba; E Klonou; E Panagiotaki; C Georgalidis; A Krokida; N Delaportas; A Lachanas; G Karaliotas; I Kaliolia
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

10.  Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness.

Authors:  Angel L M de Francisco; Peter Stenvinkel; Sophie Vaulont
Journal:  NDT Plus       Date:  2009-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.